
Merck’s Sacituzumab Tirumotecan Demonstrates Overall Survival Benefit in Phase 3 TroFuse-015 Trial for Advanced Gastroesophageal Cancer
Merck, known as MSD outside the United States and Canada, has announced positive results from the pivotal Phase 3 TroFuse-015 clinical trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC), in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival (OS) compared with treatment of physician’s choice (TPC) among patients who had received two or more prior lines of systemic therapy.
Sac-TMT is being developed by Merck following its licensing agreement with Kelun-Biotech. The investigational ADC is designed to target TROP2, a protein that is expressed in various solid tumors, and represents an important component of Merck’s expanding oncology development strategy.
The TroFuse-015 findings are significant because they represent the first time a TROP2-directed ADC has demonstrated an overall survival benefit in a global Phase 3 clinical trial involving this patient population. Patients with advanced gastroesophageal adenocarcinoma who have experienced disease progression following multiple prior systemic treatments face substantial treatment challenges and have limited therapeutic options. The results therefore provide important clinical evidence supporting further investigation of sac-TMT in this difficult-to-treat setting.
At the final analysis, patients treated with sac-TMT experienced a statistically significant and clinically meaningful improvement in overall survival compared with those receiving TPC. The treatment benefit was generally consistent across patient subgroups, regardless of TROP2 expression status.
However, sac-TMT did not meet the trial’s secondary endpoint of progression-free survival (PFS), as assessed by blinded independent central review (BICR). The study also reported a nominally improved objective response rate (ORR) favoring sac-TMT over physician’s choice of treatment. This secondary endpoint was not formally tested under the prespecified statistical analysis plan.
The safety profile of sac-TMT was consistent with findings from previously reported studies, and no new safety signals were observed. Merck plans to present the TroFuse-015 findings at an upcoming medical meeting and share the data with regulatory authorities.
Phase 3 TroFuse-015 trial meets its primary overall survival endpoint
TroFuse-015 is a pivotal global Phase 3 study designed to evaluate sac-TMT against treatment of physician’s choice in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. The trial enrolled patients whose disease had progressed after two or more previous lines of systemic therapy.
Gastroesophageal adenocarcinoma is a type of cancer affecting the stomach and the gastroesophageal junction, where the esophagus connects to the stomach. Advanced disease can be particularly challenging to manage, especially when patients have already received multiple systemic treatment regimens and their cancer has continued to progress.
For these patients, subsequent treatment decisions can be difficult because available therapies may offer limited benefit and treatment responses can vary. Improving survival and identifying additional treatment options remain important objectives in clinical research.
In TroFuse-015, sac-TMT was compared with a group of established treatment options selected by physicians. The treatment-of-physician’s-choice arm included trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. These therapies represent treatment options that may be considered for patients with advanced disease following previous systemic treatment.
The primary endpoint of the study was overall survival, which measures the time patients live following treatment assignment. At final analysis, sac-TMT demonstrated a statistically significant and clinically meaningful improvement in OS compared with TPC.
The achievement of this primary endpoint marks an important development for the investigational ADC and its clinical development program. It also distinguishes TroFuse-015 within the TROP2-directed ADC research landscape, as the company reported that this is the first global Phase 3 trial in this patient population to demonstrate an overall survival benefit with a TROP2-directed ADC.
The results suggest that sac-TMT may have a role in addressing the treatment needs of patients with advanced gastroesophageal adenocarcinoma after multiple prior lines of systemic therapy. Further evaluation of the complete clinical dataset will be important for understanding the magnitude of benefit, the treatment’s safety profile and its potential place in future treatment strategies.
Survival benefit observed across TROP2 expression subgroups
Another notable finding from TroFuse-015 was that the overall survival benefit was generally consistent across patient subgroups, regardless of TROP2 expression status.
TROP2 is a cell-surface protein that has attracted interest as a therapeutic target in oncology. Its expression in multiple tumor types has supported the development of targeted treatment approaches, including antibody-drug conjugates designed to deliver cytotoxic agents to cancer cells.
ADC technologies combine an antibody that recognizes a specific target with a linked drug payload. The antibody component is intended to guide the treatment toward cells expressing the target, while the attached payload provides the cell-killing component. This approach is designed to deliver therapeutic agents to cancer cells through a targeted mechanism.
The consistency of the overall survival findings across TROP2 expression subgroups is relevant to the ongoing evaluation of sac-TMT. It indicates that the reported survival benefit was not limited to a particular TROP2 expression subgroup in the trial’s analyses.
Nevertheless, the full clinical and biomarker data will be important for determining how TROP2 expression may relate to treatment response and for understanding the potential use of sac-TMT in different patient populations.
Merck has not yet released the complete numerical efficacy results in the announcement. The company said the data will be presented at an upcoming medical meeting, allowing the scientific community to review the detailed findings and assess their implications for clinical practice and future research.
Secondary endpoints show mixed findings
Although TroFuse-015 met its primary overall survival endpoint, the results for the secondary endpoints were mixed.
Sac-TMT did not meet the secondary endpoint of progression-free survival, which was assessed by blinded independent central review. PFS measures the time during which patients live without their disease progressing or without death occurring, according to the study’s defined criteria.
The BICR assessment is intended to provide an independent evaluation of tumor response and disease progression, helping reduce potential bias in the interpretation of imaging results. The failure to meet this secondary endpoint means that the study did not demonstrate the prespecified PFS benefit required under its statistical analysis plan.
The trial also reported a nominally improved objective response rate favoring sac-TMT compared with TPC. ORR measures the proportion of patients whose tumors demonstrate a predefined degree of reduction in size following treatment.
However, the company clarified that this endpoint was not formally tested under the prespecified analysis plan. As a result, the ORR finding should be interpreted as a nominal observation rather than a formally established statistically significant outcome.
The distinction between the primary and secondary endpoint findings is important when assessing the overall trial results. While the statistically significant OS improvement represents the study’s principal positive finding, the PFS result did not meet its secondary endpoint, and the ORR observation requires cautious interpretation.
The complete dataset, including detailed efficacy analyses and safety information, will provide further context for understanding the clinical profile of sac-TMT in this setting.
Safety profile remains consistent with previous studies
In addition to efficacy, the safety profile of an investigational cancer treatment is an important consideration, particularly among patients who have received multiple previous therapies.
According to Merck, the safety profile observed in TroFuse-015 was consistent with what had been reported in earlier studies of sac-TMT. No new safety signals were identified in the trial.
This finding provides additional information about the investigational ADC as its clinical development continues across different tumor types and treatment settings. However, detailed safety data, including the frequency and severity of adverse events, will be needed to provide a more comprehensive assessment of the treatment’s tolerability.
The company expects the forthcoming presentation of the trial results to provide an opportunity for researchers, clinicians and other members of the oncology community to examine the findings in greater detail.
Merck highlights the need for new treatment options
Marjorie Green, MD, Senior Vice President and Head of Oncology, Global Clinical Development at Merck Research Laboratories, highlighted the significance of the overall survival findings and the need for additional therapies for patients with advanced gastroesophageal adenocarcinoma.
“Sac-TMT is the first TROP2 ADC to improve OS in a global Phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC, demonstrating its potential in a particularly challenging disease setting,” said Dr. Marjorie Green. “There is a tremendous unmet need for therapies that can improve survival for these patients. We look forward to discussing these data with regulatory authorities and sharing with the scientific community on behalf of patients who may benefit.”
Her comments emphasize the importance of the trial’s primary endpoint achievement in a patient population where treatment options remain challenging. The company intends to discuss the findings with regulatory authorities and make the results available to the scientific community at an upcoming medical meeting.
The planned regulatory discussions will be an important next step in determining how the findings may support further development and potential future regulatory submissions. The announcement does not indicate that sac-TMT has received approval for this indication, and the treatment remains investigational.
Second positive Phase 3 study in Merck’s TroFuse development program
TroFuse-015 also marks the second positive Phase 3 study reported from Merck’s broader TroFuse clinical development program for sac-TMT.
The program currently includes 18 ongoing global Phase 3 trials evaluating the investigational ADC across multiple tumor types and stages of disease. According to Merck, it represents the broadest range of disease and treatment settings being evaluated for any TROP2-directed ADC to date.
The clinical development program covers a diverse group of cancers, including:
- Endometrial cancer
- Bladder cancer
- Breast cancer
- Cervical cancer
- Gastric cancer
- Non-small cell lung cancer
- Ovarian cancer
The trials span early- to late-stage disease and evaluate sac-TMT both as a monotherapy and in combination with immunotherapies. This broad development strategy is intended to assess the molecule’s potential across different cancer types and treatment settings.
Within the 18 Phase 3 studies, 14 are pursuing first-in-class opportunities to address unmet medical needs, including TroFuse-015. These studies are designed to investigate whether sac-TMT could offer new treatment possibilities in areas where additional therapeutic options are needed.
The breadth of the program reflects Merck’s investment in exploring TROP2-directed ADCs as a potential treatment approach across solid tumors. By studying sac-TMT in different disease settings, the company aims to generate evidence about its efficacy and safety as a standalone treatment and in combination with other cancer therapies.
The program also provides an opportunity to evaluate how the investigational ADC may perform across different stages of cancer and in patients with varying treatment histories. The results from individual trials will be important in determining the molecule’s potential role in specific indications.
Advancing sac-TMT research across multiple cancer types
The positive overall survival result from TroFuse-015 adds to the clinical evidence being generated through Merck’s development program. It also highlights the importance of continuing research into targeted therapies for patients whose cancers have progressed following standard treatment approaches.
For patients with advanced gastroesophageal adenocarcinoma, the availability of additional treatment options remains an important area of medical need. The TroFuse-015 findings provide evidence that sac-TMT can improve overall survival compared with physician-selected treatment options in the studied population, although further regulatory and scientific review will be required.
The absence of a PFS benefit under the study’s secondary endpoint and the nominal nature of the ORR finding also demonstrate why complete data evaluation is essential. A comprehensive understanding of clinical benefit requires consideration of multiple efficacy measures, safety outcomes and patient characteristics.
Merck plans to present the data at an upcoming medical meeting and share the findings with regulatory authorities. These next steps will allow the results to undergo further scientific and regulatory assessment.
With 18 ongoing global Phase 3 studies across multiple tumor types, the TroFuse program remains a major component of Merck’s oncology development strategy. The company is investigating sac-TMT in a wide range of cancer settings, including opportunities for use as monotherapy and in combination with immunotherapies.
The TroFuse-015 announcement represents a significant milestone for the program, as sac-TMT demonstrated an overall survival benefit in a global Phase 3 study involving patients with heavily pretreated advanced gastroesophageal adenocarcinoma. As additional trial results emerge, the broader clinical development program is expected to provide further insight into the potential applications of this investigational TROP2-directed ADC.
About TroFuse-015
TroFuse-015 is a randomized, open-label, multicenter, global Phase 3 trial (ClinicalTrials.gov,NCT06356311) evaluating the efficacy and safety of the TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) compared to the treatment of physician’s choice (TPC) in participants with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy.
The trial enrolled 473 patients who were randomized to receive either sac-TMT or TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Sac-TMT (4 mg/kg) was administered on Days 1, 15 and 29 of each six-week treatment cycle. Trifluridine-tipiracil (35 mg/m²) was administered orally twice daily on Days 1-5 and 8-12 of each four-week treatment cycle. Irinotecan (150 mg/m²) was administered on Days 1 and 15 of each four-week treatment cycle. Paclitaxel (80 mg/m²) was administered on Days 1, 8 and 15 of each four-week treatment cycle. Docetaxel (75 mg/m²) was administered on Day 1 of each three-week treatment cycle.
The study has a primary endpoint of overall survival. Secondary endpoints include progression-free survival, objective response rate, and duration of response.
About sacituzumab tirumotecan (sac-TMT)
Sac-TMT is an investigational TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a unique bifunctional linker designed with the potential to maximize payload delivery to tumor cells and minimize payload loss while circulating in the body.
TROP2 is overexpressed on tumor cells compared to healthy cells in many common cancers, and through the TroFuse clinical development program, Merck is evaluating sac-TMT in 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. The TroFuse development program spans early-to-late stage disease in more than nine disease areas and includes more than 15,000 patients worldwide. Numerous Phase 3 trials are exploring sac-TMT as monotherapy and in combination with immunotherapies, aiming to improve survival and quality of life for patients with advanced and earlier-stage cancers.
About Gastroesophageal Adenocarcinoma
Gastroesophageal adenocarcinoma comprises gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinomas (EAC).
Gastric (stomach) cancer often does not cause symptoms in its early stages, making it difficult to detect before the disease has advanced. Most gastric cancers are adenocarcinomas, accounting for approximately 90% to 95% of gastric malignancies, which develop from cells in the innermost lining of the stomach, known as the mucosa. In the U.S., it is estimated there will be approximately 31,500 new cases of gastric cancer and 10,700 deaths from the disease in 2026. Gastric cancer accounts for approximately 1.5% of all new cancers diagnosed in the U.S. each year.
Esophageal cancer starts when cells in the lining of the esophagus begin to grow out of control. In the U.S., about 68% of all new cases of esophageal cancer are EAC, and it is estimated there will be more than 14,300 new cases of EAC in 2026. Approximately 42% of EAC patients in the U.S. are diagnosed at the distant disease stage.
About the Merck and Kelun-Biotech Agreement
Sac-TMT was developed by Kelun-Biotech. Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Under an exclusive license and collaboration agreement, Kelun-Biotech has granted Merck the exclusive rights to develop, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macau and Taiwan).
Merck’s focus on cancer
Every day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 20 novel mechanisms. With one of the largest clinical development programs across more than 25 tumor types, we strive to advance breakthrough science that will shape the future of oncology.
By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncology.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.



